Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | YAP1 | P46937 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8019650 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGB5KDM4E | |
| SCHEMBL8031246 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BITGAVITGB5KDM4E | |
| SCHEMBL8032542 | 0.91 | ITGB3 (0.47) | ITGB3ITGA2BITGAVITGB5KDM4E | |
| SCHEMBL8019565 | 0.91 | ITGB3 (0.47) | ITGB3ITGA2BITGAVITGB5KDM4E | |
| SCHEMBL8030519 | 0.87 | ITGB3 (0.44) | ITGB3ITGA2BITGAVITGB5KDM4E | |
| SCHEMBL8346467 | 0.83 | KDM4E (0.43) | ITGB3ITGA2BITGAVITGB5KDM4E | |
| SCHEMBL2448063 | 0.81 | FAAH (0.63) | KDM4EPKMFAAHGPR119YAP1 | |
| SCHEMBL5766363 | 0.78 | FAAH (0.50) | KDM4EPKMFAAHGPR119HPGDS | |
| SCHEMBL8032371 | 0.78 | ITGB3 (0.51) | ITGB3ITGA2BITGAVKDM4EPKM | |
| SCHEMBL12892122 | 0.78 | ITGB3 (0.45) | ITGB3ITGA2BITGAVITGB5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680278-B2 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124804-A1 | Enantioselective process for preparing a substituted alkanoic acid | ITGA5, ITGA1, ITGB5 | ITGB3 13/4885ITGA2B 6/4885ITGAV 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.